These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 9564889

  • 1. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction.
    Lee SH, Kim SY, Lee JY, Shin MS, Dong SM, Na EY, Park WS, Kim KM, Kim CS, Kim SH, Yoo NJ.
    Lab Invest; 1998 Apr; 78(4):453-9. PubMed ID: 9564889
    [Abstract] [Full Text] [Related]

  • 2. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
    Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, Dong SM, Na EY, Kim CS, Kim SH, Yoo NJ.
    J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
    [Abstract] [Full Text] [Related]

  • 3. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.
    Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ.
    Hum Pathol; 2001 Mar; 32(3):250-6. PubMed ID: 11274632
    [Abstract] [Full Text] [Related]

  • 4. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.
    Midis GP, Shen Y, Owen-Schaub LB.
    Cancer Res; 1996 Sep 01; 56(17):3870-4. PubMed ID: 8752148
    [Abstract] [Full Text] [Related]

  • 5. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
    Lim SC.
    Oncol Rep; 2002 Sep 01; 9(1):103-7. PubMed ID: 11748465
    [Abstract] [Full Text] [Related]

  • 6. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H.
    Hepatology; 1999 Aug 01; 30(2):413-21. PubMed ID: 10421649
    [Abstract] [Full Text] [Related]

  • 7. Alternative splicing of the primary Fas transcript generating soluble Fas antagonists is suppressed in the failing human ventricular myocardium.
    Schumann H, Morawietz H, Hakim K, Zerkowski HR, Eschenhagen T, Holtz J, Darmer D.
    Biochem Biophys Res Commun; 1997 Oct 29; 239(3):794-8. PubMed ID: 9367848
    [Abstract] [Full Text] [Related]

  • 8. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis.
    Baldwin RL, Tran H, Karlan BY.
    Gynecol Oncol; 1999 Aug 29; 74(2):265-71. PubMed ID: 10419743
    [Abstract] [Full Text] [Related]

  • 9. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A.
    J Pathol; 2000 Jan 29; 190(1):20-30. PubMed ID: 10640988
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure.
    Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S, Hayashi N.
    Am J Gastroenterol; 2000 Aug 29; 95(8):2047-55. PubMed ID: 10950056
    [Abstract] [Full Text] [Related]

  • 12. Detection of occult tumor cells in lymph nodes from non-small cell lung cancer patients using reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA with the evaluation of its sensitivity.
    Maeda J, Inoue M, Okumura M, Ohta M, Minami M, Shiono H, Shintani Y, Matsuda H, Matsuura N.
    Lung Cancer; 2006 May 29; 52(2):235-40. PubMed ID: 16510209
    [Abstract] [Full Text] [Related]

  • 13. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma.
    Ma Y, Ye F, Lv W, Cheng Q, Chen H, Xie X.
    Eur J Obstet Gynecol Reprod Biol; 2008 Jun 29; 138(2):204-11. PubMed ID: 17826886
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Correlation of lymph node metastases and expression of matrix metalloproteinase-7 in patients with gastric cancer.
    Ajisaka H, Yonemura Y, Miwa K.
    Hepatogastroenterology; 2004 Jun 29; 51(57):900-5. PubMed ID: 15143943
    [Abstract] [Full Text] [Related]

  • 17. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
    Sejima T, Miyagawa I.
    Int J Urol; 2006 Mar 29; 13(3):257-64. PubMed ID: 16643620
    [Abstract] [Full Text] [Related]

  • 18. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
    Boldrini L, Faviana P, Pistolesi F, Gisfredi S, Di Quirico D, Lucchi M, Mussi A, Angeletti CA, Baldinotti F, Fogli A, Simi P, Basolo F, Fontanini G.
    Oncogene; 2001 Oct 04; 20(45):6632-7. PubMed ID: 11641789
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 04; 160(2):571-6. PubMed ID: 9679930
    [Abstract] [Full Text] [Related]

  • 20. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E.
    J Pathol; 2003 Oct 04; 201(2):268-77. PubMed ID: 14517844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.